Digital Health News Report

Reporting period: 1 June 2026 – 29 June 2026

Prepared by Woesthuis MedTech Consultancy

Focus: VC & growth investments · M&A · Market access · Clinical studies · Adoption & utilization · Urology deep-dive

Executive Summary

June 2026 confirmed three structural shifts that have defined digital health all year.

First, capital continues to concentrate in fewer but larger AI-native rounds, with voice and agentic AI capturing some of the month's biggest cheques: Assort closed a $120M Series C for specialty-care voice AI on the final day of the reporting window, Trase landed $107M for AI agents, Cadence raised $100M for chronic-care AI plus new Duke Health and Texas Health Resources partnerships, and Rylo (formerly Nagish) closed $85M to expand AI communication tools.

Second, European specialist clinical AI is rapidly catching — and in benchmark settings outperforming — generalist large language models, with Cambridge-based Corti's Symphony coding model beating mainstream LLMs by more than 25% on independent benchmarks.

Third, the European regulatory environment is fragmenting: the Digital Omnibus political deal confirmed parallel AI Act and MDR/IVDR compliance for AI-enabled medical devices — a complexity industry has called avoidable.

For European startups and scale-ups, the value premium has moved decisively toward demonstrable clinical utility, payer alignment and a credible regulatory roadmap. For US-focused vendors, the CMS/FDA RAPID coverage pathway and the FDA's evolving stance on low-risk wellness software continue to compress the time from clearance to reimbursement.

Urology had a quiet but high-quality period, anchored by Valar Labs' FDA Breakthrough Device Designation for Vesta Bladder Risk Stratify Dx, Bright Uro's expanded catheter-free urodynamics platform, Avenda Health's deployment at the University of Michigan, and the AI/AR prostate biopsy work presented at AUA 2026.

1. Venture Capital and Growth Investments

June saw a sustained flow of mid-stage and growth rounds. Voice AI, agentic AI and chronic-care platforms dominated the headline cheques. The notable rounds in chronological order:

US rounds (in reverse chronological order)

- **Assort Health — $120M Series C (29 June)** — Specialty-care voice AI platform that wants to be the transformation partner for every provider in the country. Series C announced on the final day of the reporting window.
- **Trase — $107M (26 June)** — AI agent operating system for healthcare and high-stakes industries. Funds will scale workforce and the AI agent platform.
- **xCures — $46M (25 June)** — AI-enabled Clinical Clarity Engine that aggregates and structures patient medical records to support clinical decision-making.
- **Cadence — $100M Series C (23 June)** — Remote patient monitoring for chronic conditions; announced alongside new collaborations with Duke Health and Texas Health Resources. Funds will enhance AI agents and value-based care models.

- **Prosper AI — $30M (22 June)** — Healthcare voice AI agents that automate administrative tasks including scheduling, billing and patient intakes.
- **Rylo — $85M (12 June)** — Formerly known as Nagish — AI communication tools for deaf and hard-of-hearing users, expanding from phone-call captioning into a broader AI communication platform.
- **Clair Health — $11.6M (18 June)** — Women's hormone-monitoring wearable.
- **Icarus Medical — $7.2M Series A** — Series A funding (announced 18 June).
- **Stepful — $55M (9 June)** — Hospital partnerships, new clinical education programs and AI capabilities.
- **Apoha — $36M (4 June)** — Emerged from stealth with Liquid State Intelligence — teaching machines to smell, taste and understand molecular behaviour for drug discovery.
- **Novellia — $18M (2 June)** — Patient-controlled health data platform; AI health data layer for biopharma research.
- **Optura — $17.5M Series A (8 June)** — ROAI (return on AI investment) analytics platform.

European rounds

- **Semble — £30M Series C** — UK-based care orchestration platform now powering care for roughly 10 million patients (~1 in 6 people in the UK). Round led by Revaia with participation from Partech, Mercia Ventures and Octopus Ventures. Capital to scale AI-driven care orchestration across the UK and France. Announced first week of June.
- **Thena Capital — £45M debut fund** — Female-GP-led debut fund targeting up to 25 early-stage healthcare and MedTech startups, with an explicit thesis around AI in clinical pathways. Closed 12 June.
- **01Health — $15M Series A** — UK healthtech platform raised to scale its specialist healthcare infrastructure. Announced 12 June.
- **OurMind — €2.1M** — Dutch startup raised new capital to scale its AI-driven mental-health platform. Announced 12 June. One of the few EU-mainland mental-health rounds of the period.
- **Uncovr — $7M** — UK-based, raised to automate post-operative documentation and workflow intelligence for surgeons. Led by Index Ventures. A clear example of the "software envelope around the surgical act" thesis several European VCs flagged this month.
- **Hypervision Surgical — £17M** — UK hyperspectral imaging in the operating theatre, raised during June. Part of the surgical-AI capital wave.

Latin America

- **Telepatia — $33M (19 June)** — Brazil-based startup backed by a16z; clinical platform combining AI documentation, clinical decision support and a suite of AI healthcare employees. Notable as the largest LatAm digital health round of the month and a signal that US investors are looking beyond domestic markets.

Read-through for investors and operators

Three patterns dominated the month. First, voice and agentic AI captured a disproportionate share of capital — Assort, Trase, Cadence, Prosper AI and Telepatia together accounted for more than $390M, signalling that investors are now willing to underwrite agent-based platforms at growth-stage scale.

Second, surgical and procedural AI continues to attract substantial European interest because hospital capital budgets, high per-procedure value and a natural regulatory moat make the unit economics defensible. Third, vertical practice management — long considered underbuilt in Europe — is finally catching meaningful capital, with Semble's £30M Series C the standout.

2. Mergers and Acquisitions

June was lighter on headline M&A than the preceding two months, but consolidation continued at the platform-acquires-feature level. The most visible activity came from prior-month deals continuing to integrate — Quantum Health's CirrusMD integration, Chartis' absorption of Leap AI, and Oura's integration of Galen AI all generated meaningful June commentary around scaled platforms absorbing clinical-AI capability ahead of foundation-model entrants. Carrying over from May, the Infosys close of Optimum Healthcare IT (5 May) remained the most visible services-side transaction in market commentary. Cadence's $100M Series C, paired with new Duke Health and Texas Health Resources collaborations, also functioned as a quasi-consolidation signal: scaled chronic-care platforms locking in flagship health-system relationships ahead of any wave of strategic acquisitions. Strategic M&A activity is expected to accelerate again in Q3 as scaled digital health platforms protect their moats against general-purpose AI entrants such as OpenAI.

3. Market Access and Regulatory

United States

The CMS/FDA RAPID (Regulatory Alignment for Predictable and Immediate Device) coverage pathway, launched in May, continued to dominate market-access conversations through June. It enables clinical evidence generated for FDA review to also support Medicare coverage decisions, materially compressing the historical lag between clearance and reimbursement for breakthrough digital and AI-enabled devices. Several vendors are now openly building their evidence dossiers against the RAPID framework. OpenEvidence — the AI clinical decision support platform reportedly used daily by more than 40% of US physicians — was widely reported in late June to have begun engaging FDA on a formal regulatory pathway, a notable transition for a tool that grew without regulation. The FDA's 2026 TEMPO guidance continued to clarify the boundary between general-wellness wearables and regulated SaMD, with a more bifurcated regime emerging: lighter for wellness, faster for breakthrough.

Europe

The single most important European policy development of the period was the political agreement on the Digital Omnibus amending the EU AI Act. MedTech Europe had lobbied for AI-enabled medical devices to follow a single, sector-specific compliance pathway under existing medical regulations. The final deal instead confirms parallel, overlapping high-risk requirements from both the AI Act and the MDR. Industry leaders called this an unnecessary layer of complexity for an already heavily regulated sector. Attention has now shifted to the targeted MDR revision as the route to a workable solution.

At the MedTech Forum 2026 in Stockholm, European device CEOs collectively pushed for structural predictability through an MDR/IVDR overhaul. MedTech Europe filed a 39-page position paper backing simplification proposals that the EU Parliament estimates could save up to €3.3 billion annually. The European Medicines Agency's newly launched innovative device pilot — a precursor to a formal US-style breakthrough device pathway for Class III and implantable devices — was widely praised. EU-level regulatory sandboxes for testing AI hardware in real-world settings are being fast-tracked. The European Commission has separately committed €63.2M to AI health innovation and is building the Cancer Image Europe infrastructure, targeting access to 60 million oncology images by end-2026.

United Kingdom

The MHRA published its draft Medical Devices (Amendment) Regulations 2026, introducing an international reliance pathway. Manufacturers with clearance in trusted markets (notably FDA) will be able to access the Great Britain market through a drastically simplified review process — a meaningful tailwind for US-cleared digital health companies eyeing UK expansion.

Notable AI / digital clearances and designations

Building on May's wave of clearances, the period saw continued visibility for Spectral AI's DeepView (De Novo for burn-wound healing prediction), Abbott's Ultreon 3.0 (510(k) + CE Mark for AI-augmented coronary imaging), Siemens Healthineers' six new Artis interventional systems with the Optiq AI imaging chain (510(k)), and RIVANNA's Accuro XV AI ultrasound (510(k)). Urology-specific milestones are covered in section 6.

4. Notable Clinical Studies and Evidence

- **Corti's Symphony model outperforms generalist LLMs —** Cambridge-headquartered specialised medical AI lab Corti's domain-specific medical coding model, Symphony, outperformed mainstream models including OpenAI and Anthropic by more than 25% on independent clinical accuracy benchmarks. This is the clearest evidence to date that hyper-specialised vertical medical AI can decisively outperform generalist LLMs in regulated clinical settings — a meaningful argument for European specialist vendors against US foundation-model players.
- **Nature: general-purpose LLMs outperform healthcare-specific models (18 June) —** A Nature paper published 18 June suggested that general-purpose LLMs outperform fine-tuned healthcare-specific models out of the box — the direct counterpoint to the Corti finding above. The Nature result tested broad medical-knowledge tasks rather than narrow coding accuracy, illustrating that the "specialist vs generalist" debate is now task-specific rather than settled.
- **AI outperforms physicians, just not at medicine (22 June) —** Two Nature studies published the same week showed AI continues to outperform physicians — though, as the Digital Health Wire summary noted, not at actual medicine, but at the structured-reasoning subsets that have always favoured machine pattern-matching. Important context for any vendor positioning AI as a clinician replacement.
- **Patients want AI, as long as there is no copay — Johns Hopkins / npj Digital Medicine (11 June) —** Johns Hopkins researchers published in npj Digital Medicine that patients are warming up to AI in care delivery — provided there is no copay. A cleaner signal than most patient-acceptance surveys: utility plus economics, not utility alone.
- **Abridge keynote with Eli Lilly and Nvidia (15 June) —** Abridge held its first keynote on 15 June, unveiling a new platform alongside partnerships with Eli Lilly and Nvidia. A notable signal that AI scribing has matured into a platform play with pharma and infrastructure partners.
- **Rock Health: wearables are here, the outcomes are not (4 June) —** Rock Health published an analysis showing that despite continued wearable adoption, hard clinical outcomes remain elusive — an important reality check for both investors and clinical buyers as wearables move into reimbursable workflows.
- **AI-driven AR prostate biopsy at AUA 2026 —** Researchers from the University of Miami Miller School of Medicine's Desai Sethi Urology Institute presented a video-documented OR experience using AI to drive AR for MRI–ultrasound fusion prostate biopsy. The platform is described as nearly

ready for clinical use but has not yet been compared head-to-head with standard fusion biopsy. Outstanding hurdles include FDA clearance, accuracy drift under probe pressure, and headset-fatigue. Presented at AUA 2026 (Washington DC).

- **JAMA Network: the case for primary care as a public utility (1 June) —** A Harvard / UCSF analysis in JAMA Network made the case for treating primary care as a public utility — a structural argument with direct implications for telehealth and primary-care digital vendors who depend on the existing fragmented payer mix.

5. Market Adoption and Utilization

Concrete platform-scale utilization disclosures continued to define the new benchmarks investors are using when valuing late-stage digital health:

- **OpenEvidence —** Used daily by more than 40% of US physicians, with a $100M ARR. Remains the most-cited utilization benchmark in the market and reportedly entered FDA territory during June.
- **Cadence — health-system traction —** $100M Series C plus newly announced Duke Health and Texas Health Resources collaborations cement Cadence as one of the leading chronic-care RPM platforms; a clear adoption signal that health systems are committing long-term to AI-enabled remote monitoring.
- **Semble —** Powers care for roughly 10 million patients in the UK (~1 in 6 of the population), establishing it as the dominant care-orchestration platform in NHS-adjacent markets.
- **Whoop —** Running at roughly $1.1B annual revenue run-rate, ahead of a reported IPO. The clearest data-point that consumer wearables have crossed into mainstream digital-health scale.
- **Glooko — Annual Diabetes Report —** Glooko's 2026 Annual Diabetes Report (published 22 June) outlined the scale at which the platform is now operating and the shift it sees from retrospective data review toward prioritised, real-time action — a structural change in how connected diabetes care is delivered.
- **CMMI ACCESS Model —** CMS reports that applications for participation in the CMMI ACCESS Model exceeded expectations, drawing nearly every major payer into a common value-based payment framework — a meaningful structural tailwind for digital health vendors aligned to outcome-based contracts.

6. Urology Deep-Dive

Urology had a quiet but high-signal period for digital health, with several developments worth flagging given your specialty focus. Most of the regulatory milestones landed in mid-May but were widely covered through the Urology Times June recap and continued press throughout June.

6.1 Regulatory milestones

- **Valar Labs — Vesta Bladder Risk Stratify Dx —** FDA granted Breakthrough Device Designation (announced 15 May, widely covered through June) to this AI-enabled digital pathology test for risk stratification in bladder cancer. This is one of the most significant AI-urology regulatory milestones of 2026 and positions Valar Labs to leverage the new RAPID coverage pathway. Worth monitoring closely.

- **Bright Uro — Glean Abdominal Sensor** — FDA 510(k) clearance (7 May, covered in the June urology recap) for the Glean Abdominal Sensor, expanding the Glean Urodynamics System to enable catheter-free multichannel urodynamics — capturing abdominal and detrusor pressure alongside cystometry and pressure-flow measurements without catheter interference. A genuine workflow shift for office urodynamics.
- **Aurie Reusable No-Touch Intermittent Catheter System** — FDA de novo authorisation (11 May, in June recap) for a reusable no-touch intermittent catheter system — a category that has not seen meaningful innovation in years and is highly relevant for chronic neurogenic bladder patients.
- **Revvity — automated total testosterone ChLIA assay** — FDA clearance (13 May) for an automated chemiluminescence immunoassay (ChLIA) for total testosterone measurement — a workflow upgrade for men's-health diagnostic labs.
- **Generic enzalutamide tentative approval (26 June)** — The FDA granted tentative approval on 26 June to generic enzalutamide tablets — not strictly digital health, but a meaningful market-shaping event for the prostate-cancer treatment landscape that digital urology vendors operate alongside.

6.2 Commercial deployment and market adoption

- **Avenda Health — Unfold AI at University of Michigan Health** — Avenda Health announced the deployment of its AI-guided prostate cancer treatment-planning platform at the University of Michigan Health system — bringing the technology to the Midwest for the first time. Unfold AI is notable as the first AI urology tool to receive a Category III CPT code from the AMA, materially de-risking the reimbursement path. The Michigan deployment is a significant adoption signal for AI-guided focal therapy planning.

6.3 Funding

- **Urologic Health — $11M seed** — Closed in mid-May, this New Jersey / Or Yehuda Israel-based developer of non-invasive urodynamic and bladder-function monitoring devices is one of the few urology-pure-play digital health companies to raise in 2026. Adjacent to the Bright Uro thesis on the office-based urodynamics workflow.
- **Lucida Medical** — UK-based AI prostate cancer diagnostics platform (raised £8.7M in March, with continued June press coverage of expanded NHS deployment). One of the most credible European urology-AI plays and a strong example of how UK-cleared digital diagnostics can leverage the upcoming MHRA international reliance pathway in reverse — using NHS adoption as evidence for global expansion.

6.4 Clinical and translational science

- **AUA 2026 — AI/AR prostate biopsy** — University of Miami Miller School / Desai Sethi Urology Institute's AI-driven AR-guided MRI-fusion prostate biopsy is a strong signal that AR + AI is moving from research curiosity toward clinical adoption in the prostate biopsy workflow — though FDA clearance, data ownership and registration drift remain meaningful hurdles.
- **AUA 2026 — overactive bladder and neuromodulation** — AUA 2026 also featured significant content from Miller School urologists on overactive bladder and neuromodulation — a quietly growing area where digital control of neuromodulation devices is creating new opportunities for digital-first urology vendors.
- **AI cancer-gene discovery for breast and prostate cancer** — A Vanderbilt-led paper (published end of May, widely picked up in June) showed an AI technique that improves cancer-gene

discovery for both breast and prostate cancer — a long-cycle but meaningful signal for biomarker-driven urology diagnostics.

6.5 What to watch in urology

- First commercial wins under RAPID — Valar Labs is the candidate to watch given its fresh Breakthrough Device Designation.
- AI-guided prostate biopsy moving from research presentations to first FDA submissions.
- Catheter-free urodynamics adoption curves at Bright Uro — a leading indicator for office-based digital urology workflows.
- Continued NHS expansion of Lucida Medical as a template for European AI-urology commercialization.
- Whether any of the major men's-health telehealth platforms (Hims, Ro) make an explicit move into clinical urology versus their current lifestyle-medication focus.

7. Outlook into July 2026

- First public RAPID-pathway test cases will set the precedent for digital-health reimbursement timeline compression.
- Expect continued telehealth and behavioral-health M&A as scaled platforms defend against foundation-model entrants.
- European policy: the targeted MDR revision is now the only realistic vehicle for resolving the AI Act / MDR overlap.
- UK: the MHRA international reliance pathway, once final, will materially reshape go-to-market sequencing for US-cleared digital health companies.
- Voice and agentic AI fundraising will likely remain the dominant capital theme into Q3, given the Assort, Trase, Cadence and Prosper AI rounds of late June.
- Urology specifically: watch for Valar Labs commercial activity, Avenda Health network expansion, and the first AI-AR prostate biopsy FDA submission.

Sources

MobiHealthNews; Fierce Healthcare; Healthcare Dive; MedCity News; Digital Health Wire (issues #469–472, June 2026); Urology Times (FDA updates in urology recap, 3 June 2026); PRNewswire; University of Miami Miller School of Medicine; Vanderbilt Health News; GoHub Ventures (H1 2026 European digital health funding overview, 25 June 2026); Nelson Advisors / healthcare.digital (This Week in European MedTech and HealthTech — 5 and 12 June 2026); RamaOnHealthcare; Nature; npj Digital Medicine; JAMA Network; Rock Health; FDA Digital Health Center of Excellence; ATA Action.